A written price shows what your care may cost

The written total matters more than the starting price

The written amount needs to cover the exam, the care, and later office visits. It also needs to name any charge that isn't included. If there's a payment plan, interest raises the final cost, so don't count only the first receipt.

Time away from work or family costs something too. Add the drive, a ride home, and any help you'll need afterward. One nearby visit may be easy, while several return trips can strain your week. That time isn't free.

Decide what change would make the expense worthwhile, such as easier walking or better sleep. Ask when you might notice that change and when spending would stop if nothing improves. The office may not know for certain, and an honest limit can protect your wallet.

Insurance covers the service, not merely the office

An office may take your insurance even when one service isn't covered. Call your health plan with the exact service before you pay. Ask about approval and your deductible, the amount you must pay before the plan starts paying. Keep the answer where you can find it.

Medicare doesn't have a nationwide rule that pays for platelet-rich plasma (PRP), a shot made by spinning your blood until one part is concentrated, when it is used for low back soreness. Other plans may pay for an exam, medicine, or physical therapy while refusing that shot. The answer won't cover every service.

For another price to check, QC Kinetix offers non-surgical regenerative treatments, the clinic's name for choices such as concentrated PRP given by a trained health worker after an exam. These services may be paid in cash, so a written total gives you time to decide. Read it at home when you aren't sore or rushed. If a charge isn't clear, ask again.

Sources

1. CMS covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and then only inside an approved coverage-with-evidence-development clinical study. There is no national Medicare coverage for PRP in low back pain of any origin, and commercial plans generally follow with musculoskeletal PRP non-coverage policies.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma - Coverage with Evidence Development.. CMS.gov, 2025.

2. The 2025 ASIPP regenerative-therapy guideline for chronic low back pain - written by the specialty society that performs these procedures - grades the evidence as Level III (fair) for intradiscal PRP, Level III (fair) for intradiscal bone marrow concentrate, Level III (fair) for epidural PRP, Level IV (limited) for facet joint PRP and MSC injections, Level IV (limited) for sacroiliac joint PRP, and very low for functional-spine-unit injections. All 19 recommendations are consensus-based rather than evidence-driven, the panel names the scarcity of high-quality studies as the primary limitation, and it states that most of these therapies are not covered by commercial insurance.

   Manchikanti L, Navani R, Navani A, et al. — Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).. Pain Physician, 2025.

3. In January 2025 federal district court orders permanently banned the co-founders of the Stem Cell Institute of America and several related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. On summary judgment the court found the defendants had published false and misleading advertisements about the efficacy and approval of stem cell injections for a range of conditions. Their clinic charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers.

   Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties.. FTC.gov, 2025.

4. A survey of internet-based marketing claims documented that direct-to-consumer promotion of unapproved stem cell interventions - long assumed to be a feature of countries with lax regulation - is widespread among businesses based in the United States, and concluded that regulatory agencies must better oversee this marketplace.

   Turner L, Knoepfler P — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

5. A 2024 systematic review and SINGLE-ARM meta-analysis of intradiscal regenerative therapies found only 8 randomised trials and 8 observational studies in the entire literature, and graded the evidence 'fair (Level III) with limited certainty', naming the paucity of high-quality studies as its central limitation. A single-arm meta-analysis pools before-and-after change without a comparison group, so it cannot separate the injection from natural history or placebo.

   Manchikanti L, Knezevic E, Knezevic NN, et al. — Effectiveness of Intradiscal Regenerative Medicine Therapies for Long-Term Relief of Chronic Low Back Pain: A Systematic Review and Meta-Analysis.. Pain Physician, 2024.

6. The 2023 Cochrane review of spinal cord stimulation for low back pain included 13 studies and 699 participants and found NO study evaluated pain at 12 months or beyond. At six months, moderate-certainty evidence from the single available placebo-controlled trial showed SCS probably does not improve back or leg pain, function or quality of life versus placebo. In one study 13 of 42 people (31%) required revision surgery within 24 months. The authors state the data 'do not support the use of SCS to manage low back pain outside a clinical trial.'

   Traeger AC, Gilbert SE, Harris IA, Maher CG — Spinal cord stimulation for low back pain.. Cochrane Database of Systematic Reviews, 2023. DOI: 10.1002/14651858.CD014789.pub2.

7. A meta-analysis of 35 placebo-controlled randomised trials found NSAIDs reduce spinal pain and disability, but by an amount below the threshold for clinical importance: six people must be treated with an NSAID rather than placebo for one additional person to achieve clinically important pain reduction, and NSAIDs raised the risk of gastrointestinal reactions 2.5-fold. The authors conclude that no simple analgesic provides clinically important effects for spinal pain over placebo.

   Machado GC, Maher CG, Ferreira PH, et al. — Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis.. Annals of the Rheumatic Diseases, 2017. DOI: 10.1136/annrheumdis-2016-210597.